1.
TexMex
@TraderTexMex
$SNGX Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte New Drug Application in the Treatment of… twitter.com/i/web/status/1…
14 Feb 23
copy & paste +upvote -downvote $SNGX Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of… https://t.co/UJhkbTd0ty
2.
TexMex
@TraderTexMex
$CARA Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA (difelikefalin) injection for the t… twitter.com/i/web/status/1…
23 Aug 21
copy & paste +upvote -downvote $CARA Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the t… https://t.co/RXwkhOjU7Z
3.
4.
5.
6.
7.
TexMex
@TraderTexMex
$OCUL Ocular Therapeutix Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release… twitter.com/i/web/status/1…
05 Aug 21
copy & paste +upvote -downvote $OCUL Ocular Therapeutix™ Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release… https://t.co/ZX8vHR70zr
TexMex
@TraderTexMex
$LMNL Liminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim (plasminogen, human-tvmh)
04 Jun 21
copy & paste +upvote -downvote $LMNL Liminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim® (plasminogen, human-tvmh)
TexMex
@TraderTexMex
Congrats $BB for pulling this together in less than 10 hours - impressive pic.twitter.com/C8vds449tV
Retweet of status by @InvestorsLive
25 Jan 21
copy & paste +upvote -downvote Congrats $BB for pulling this together in less than 10 hours - impressive 🤫 https://t.co/C8vds449tV
TexMex
@TraderTexMex
$MGNX MacroGenics Announces FDA Approval of MARGENZA for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
16 Dec 20
copy & paste +upvote -downvote $MGNX MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
TexMex
@TraderTexMex
$NAOV NanoVibronix Files U.S. Patent Application for PainShield for Delivery of Cannabinoids for Alleviation of Chronic and Acute Pain
29 Sep 20
copy & paste +upvote -downvote $NAOV NanoVibronix Files U.S. Patent Application for PainShield® for Delivery of Cannabinoids for Alleviation of Chronic and Acute Pain
8.
9.
10.
11.
TexMex
@TraderTexMex
Retail investors realizing some risk in small-cap bio's. Things have slowed.
$ACST 68% after trial failure.… twitter.com/i/web/status/1…
$ACST 68% after trial failure.… twitter.com/i/web/status/1…
02 Sep 20
copy & paste +upvote -downvote Retail investors realizing some risk in small-cap bio's. Things have slowed.
$ACST ⬇ 68% after trial failure.… https://t.co/2tEvvrv2OI
TexMex
@TraderTexMex
$MTNB Matinas BioPharma Completes Enrollment of ENHANCE-IT Study of MAT9001 Against Vascepa
Data Q1 2021
Data Q1 2021
27 Aug 20
copy & paste +upvote -downvote $MTNB Matinas BioPharma Completes Enrollment of ENHANCE-IT Study of MAT9001 Against Vascepa®
Data Q1 2021
TexMex
@TraderTexMex
DFC says Kodak deal on hold
$KODK
Nothing like a good Government sponsored pump and dump
13wham.com/news/local/dfc…
$KODK
Nothing like a good Government sponsored pump and dump
13wham.com/news/local/dfc…
Retweet of status by @InvestorsLive
08 Aug 20
copy & paste +upvote -downvote DFC says Kodak deal on hold
$KODK
Nothing like a good Government sponsored pump and dump 👌
https://t.co/4S8f02BGm8
TexMex
@TraderTexMex
$CHMA Chiasma Announces FDA Approval of MYCAPSSA (Octreotide) Capsules, the First and Only Oral Somatostatin Analog
26 Jun 20
copy & paste +upvote -downvote $CHMA Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin Analog
...but wait! There's more!
1.
fakhright
@fakhright
astaghfirullah peng.krim guaaaaaaaa..............a *salto sambil solat*
14 Jan 13
copy & paste +upvote -downvote astaghfirullah peng.krim guaaaaaaaa..............a *salto sambil solat* 🙈🙈🙊